SPRC
SciSparc Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.51
+1.35%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.48
From 52W high−91.77%
Volume2762.00
Market cap$2.62M
P/E (TTM)—
P/S (TTM)3.1x
Div yield—
Key dataSep 18, 2026
Open
$4.48
From 52W high
−91.77%
Volume
2762.00
Market cap
$2.62M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
31.2
MomentumView details →
1D Return
+1.35%
YTD Return
−63.36%
SummaryUpdated Dec 1, 2025
SciSparc Ltd. (NASDAQ:SPRC) is a specialty clinical-stage pharmaceutical company founded in 2004 and headquartered in Tel Aviv-Yafo, Israel. Originally incorporated as Therapix Biosciences Ltd., the company rebranded to SciSparc in January 2021 and went public on NASDAQ in August 2021. The company focuses on developing therapeutic drugs based on cannabinoid molecules, targeting various neurological and psychiatric conditions through its pipeline of investigational treatments.
Similar companies
Latest newsMore news →
SciSparc's subsidiary NeuroThera Labs announced it is pursuing FDA Orphan Drug Designation for its drug candidate SCI-110 for treating adult Tourette Syndrome, and engaged government affairs firm RK Strategies.18d agoSciSparc's subsidiary NeuroThera Labs announced continued advancement in participant enrollment for the clinical trial of its SCI-210 treatment for autism spectrum disorder symptoms.20d agoNeuroThera Labs Inc. announced a share consolidation of its outstanding common shares on a 1-for-14 basis, effective after a shareholder resolution passed on January 8, 2026.23d ago